Ascentage Pharma Group International (NASDAQ:AAPG) Reaches New 1-Year Low – Should You Sell?

Shares of Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG) hit a new 52-week low during trading on Wednesday . The stock traded as low as $15.01 and last traded at $18.9690, with a volume of 501 shares traded. The stock had previously closed at $18.98.

Analysts Set New Price Targets

A number of research analysts recently issued reports on AAPG shares. B. Riley Financial initiated coverage on shares of Ascentage Pharma Group International in a research report on Wednesday, June 10th. They set a “buy” rating and a $45.00 target price on the stock. BTIG Research reaffirmed a “buy” rating and issued a $48.00 price target on shares of Ascentage Pharma Group International in a research note on Monday, June 15th. Deutsche Bank Aktiengesellschaft initiated coverage on shares of Ascentage Pharma Group International in a report on Friday, April 24th. They set a “buy” rating and a $40.00 price objective on the stock. Finally, Raymond James Financial reissued a “buy” rating on shares of Ascentage Pharma Group International in a research report on Wednesday, June 10th. Two equities research analysts have rated the stock with a Strong Buy rating and eight have given a Buy rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Buy” and an average target price of $46.43.

Ascentage Pharma Group International Trading Down 0.3%

The business has a fifty day moving average of $18.12 and a 200-day moving average of $21.48. The company has a debt-to-equity ratio of 0.57, a current ratio of 1.79 and a quick ratio of 1.77.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the business. Citadel Advisors LLC acquired a new stake in shares of Ascentage Pharma Group International in the 3rd quarter worth about $383,000. Hsbc Holdings PLC acquired a new position in Ascentage Pharma Group International during the 2nd quarter valued at about $391,000. Finally, UBS Group AG boosted its stake in Ascentage Pharma Group International by 149.4% during the 3rd quarter. UBS Group AG now owns 18,345 shares of the company’s stock valued at $716,000 after purchasing an additional 10,988 shares during the last quarter.

About Ascentage Pharma Group International

Ascentage Pharma Group International is a clinical‐stage biopharmaceutical company focused on developing small‐molecule therapeutics that modulate programmed cell death pathways, including the Bcl‐2 family and the MDM2–p53 axis. Its pipeline features orally bioavailable inhibitors such as APG-2575, a selective Bcl-2 inhibitor, and APG-115, a potent MDM2 antagonist, both aimed at reactivating apoptosis in cancer cells across hematologic malignancies and solid tumors.

Founded in 2008 by biotechnology entrepreneur Dr.